Search Results - "Cedena Romero, María Teresa"

Clinical and genetic features of congenital dyserythropoietic anemia (CDA) by Moreno‐Carralero, María‐Isabel, Horta‐Herrera, Saul, Morado‐Arias, Marta, Ricard‐Andrés, María‐Pilar, Lemes‐Castellano, Angelina, Abio‐Calvete, Mariola, Cedena‐Romero, María‐Teresa, González‐Fernández, Fernando‐Ataulfo, Llorente‐González, Laura, Periago‐Peralta, Adela‐María, de‐la‐Iglesia‐Íñigo, Silvia, Méndez, Manuel, Morán‐Jiménez, María‐José

“…Introduction Congenital dyserythropoietic anemias (CDA) are characterized by hyporegenerative anemia with inadequate reticulocyte values, ineffective…”
Get full text

PB1781: THE APPLICATION OF CF‐DNA FOR NGS MRD STUDIES IN PATIENTS WITH LMA IMPROVES THE SENSITIVITY OF THE METHOD WITH RESPECT TO CTC by Sánchez‐Redondo, Noemí Álvarez, Martin, Alejandro, Dorado, Sara, Rufián, Laura, Rodriguez, Margarita, Heredia, Yanira, Robles, Maria Calbacho, Romero, Maria Teresa Cedena, Martinez‐Lopez, Joaquín, Barrio, Santiago, Diaz, Rosa Ayala

Get full text

P702: APPLICATION OF NEXT GENERATION SEQUENCING (NGS) FOR MINIMAL RESIDUAL DISEASE (MRD) AND CHIMERISM MONITORING IN MYELODYSPLASTIC SYNDROME (MDS) AFTER ALLOGENIC STEM CELL TRANSPLANTATION (ASCT) by Zamanillo, Irene, Barrio, Santiago, Martin, Alejandro, Dorado, Sara, Heredia, Yanira, Rodriguez, Margarita, Rapado, Inmaculada, Isabel Jimenez Ubieto, Ana, Ayala Diaz, Rosa, Martinez‐Lopez, Joaquín, Teresa Cedena Romero, Maria

Get full text

S256: HLA‐E/NKG2A CHECKPOINT DRIVES MULTIPLE MYELOMA RESISTANCE TO CAR‐NK THERAPY by Encinas, Jessica, García‐Ortiz, Almudena, Maroto‐Martín, Elena, Castellano, Eva, Oliva, Raquel, Alonso Fernández, Rafael, Teresa Cedena Romero, Maria, Leivas, Alejandra, Martín‐Antonio, Beatriz, Suñe, Guillermo, Lee, Dean A., Powell, Daniel J., Río, Paula, Martinez‐Lopez, Joaquín, Valeri, Antonio

Get full text

Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes by Mosquera Orgueira, Adrian, Perez Encinas, Manuel Mateo, Diaz Varela, Nicolas A, Mora, Elvira, Díaz‐Beyá, Marina, Montoro, María Julia, Pomares, Helena, Ramos, Fernando, Tormo, Mar, Jerez, Andres, Nomdedeu, Josep F, De Miguel Sanchez, Carlos, Leonor, Arenillas, Cárcel, Paula, Cedena Romero, Maria Teresa, Xicoy, Blanca, Rivero, Eugenia, Orbe Barreto, Rafael Andres, Diez‐Campelo, Maria, Benlloch, Luis E., Crucitti, Davide, Valcárcel, David

“…Myelodysplastic neoplasms (MDS) are a heterogeneous group of hematological stem cell disorders characterized by dysplasia, cytopenias, and increased risk of…”
Get full text

P703: THE AIPSS‐MDS MACHINE LEARNING MODEL PREDICTS OVERALL SURVIVAL AND LEUKEMIC TRANSFORMATION IN CMML: AN ANALYSIS OF THE SPANISH REGISTRY OF MDS by Mosquera‐Orgueira, Adrian, Mateo Perez Encinas, Manuel, Diaz Varela, Nicolas, Wang, Yu‐Hung, Mora, Elvira, Diaz‐Beya, Marina, Julia Montoro, Maria, Pomares Marin, Helena, Ramos Ortega, Fernando, Tormo, Mar, Jerez, Andres, Nomdedeu, Josep, Migue Sanchez, Carlos, Arenillas, Leonor, Carcel, Paula, Teresa Cedena Romero, Maria, Xicoy Cirici, Blanca, Rivero Arango, Eugenia, Andrés Del Orbe Barreto, Rafael, Benlloch, Luis, Lin, Chien‐Chin, Tien, Hwei‐Fang, Díez Campelo, María, Crucitti, Davide, Valcárcel, David

Get full text

Treatment Patterns and Overall Survival in Patients with Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry by Diez-Campelo, María, Benlloch, Luis E., Sasse, Emma, Wormser, David, Hernandez Donoso, Leyla, Colicino, Silvia, Bernal, Teresa, Molero Yordi, Antonieta, Tormo, Mar, Arnan Sangerman, Montserrat, Sanz, Guillermo, Díaz-Beyá, Marina, Cedena Romero, María Teresa, Jerez, Andres, Merchán, Brayan, Valcárcel, David

“…Background: The Revised International Prognostic Scoring System (IPSS-R) classifies pts with MDS into risk categories, from very low-risk (vLR) to very…”
Get full text

Management of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) - Data from the Spanish PNH Registry by De La Iglesia Iñigo, Silvia, Notario McDonell, Cristina, Gaya Valls, Anna, Cedena Romero, María Teresa, Gómez Roncero, María Isabel, Arrizabalaga Amunchastegui, Beatriz, Monteserin Monteserin, Carmen, Lavilla Rubira, Esperanza, Villegas Martínez, Ana María

“…Introduction: Patients with PNH often need surgery due to disease-related complications. However, surgery, anesthesia, and possible surgical complications,…”
Get full text

Parallel Monitoring of Measurable Residual Disease and Chimerism By NGS in Myelodysplastic Syndrome after Allogenic STEM Cell Transplant by Zamanillo, Irene, Barrio, Santiago, Martín-Muñoz, Alejandro, Dorado, Sara, Ballesteros, Ana K, Ruiz-Heredia, Yanira, Rodriguez, Margarita, Martinez-Laperche, Carolina, Martín, Sandra, Ferrer Lores, Blanca, Martin Castillo, Ivan, Rapado, Inmaculada, Ayala, Rosa, Martinez-Lopez, Joaquin, Cedena Romero, Maria Teresa

“…Background: Minimal Residual Disease (MRD) and chimerism monitoring in patients with Myelodysplastic Syndrome (MDS) is essential to track and quantify the…”
Get full text

Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS) by Wei, Andrew H., Breccia, Massimo, Ooi, Melissa, Cedena Romero, Maria Teresa, Ciceri, Fabio, Erba, Harry P., Gaur, Anil, Sechaud, Romain, Halilovic, Ensar, Kuenzle, Brigitte, Fabre, Claire, Porkka, Kimmo

“…Background: Treatment options for patients (pts) with relapsed/refractory (r/r) AML and HR-MDS who cannot tolerate standard therapy are limited, and innovative…”
Get full text

Clinical Significance of Measurable Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Chimeric Antigen Receptor (CAR) T Cells and T-Cell Engagers (TCE) by Zabaleta, Aintzane, Puig, Noemi, Cedena Romero, Maria Teresa, Perez, Jose J, Moreno, Cristina, Tamariz-Amador, Luis-Esteban, Rodriguez Otero, Paula, Gonzalez-Calle, Veronica, Lopez Corral, Lucia, Rey-Búa, Beatriz, Puertas Martínez, Borja, Miras, Fatima, Sanchez-Pina, Jose, Lopez, Nieves, Martinez-Lopez, Joaquin, Mateos, Maria Victoria, San-Miguel, Jesus, Paiva, Bruno

“…Background: CAR T cells and TCE are approved for the treatment of RRMM and are being investigated in newly diagnosed pts. Because their mode of action differs…”
Get full text

GEM2017FIT Trial: Induction Therapy with Bortezomib-Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) Versus Carfilzomib, Lenalidomide and Dexamethasone (KRd) Plus/Minus Daratumumab (D), 18 Cycles, Followed By Consolidation and Maintenance Therapy with Lenalidomide and Daratumumab: Phase III, Multicenter, Randomized Trial for Elderly Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients Aged between 65 and 80 Years by Mateos, Maria-Victoria, Paiva, Bruno, Cedena Romero, Maria Teresa, Puig, Noemi, Sureda Balari, Anna Maria, Oriol, Albert, Ocio, Enrique M, Rosiñol, Laura, González-Montes, Yolanda, Bargay, Juan Jose, Gonzalez Garcia, Esther, Hernández Garcia, Miguel Teodoro, Ramirez, Angel, Suarez-Cabrera, Alexia, Blanchard, María-Jesús, Garzón, Sebastián, Casado Montero, Luis Felipe, Cabanas Perianes, Valentin, Pérez De Oteyza, Jaime, Gironella, Mercedes, Martinez-Lopez, Joaquin, -Teruel, Ana-Isabel, Delgado, Pilar, Prieto, Elena, Lahuerta Palacios, Juan Jose, Bladé, Joan, San Miguel, Jesus

“…Background: In transplant-ineligible patients (pts) with NDMM, VMP and Rd have been standards of care. The Spanish Myeloma Group examined induction with VMP…”
Get full text

Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial by Gonzalez-Calle, Veronica, Rodriguez Otero, Paula, Rey-Bua, Beatriz, De La Rubia, Javier, De Arriba, Felipe, Cabañas, Valentin, Garcia, Esther González, Ocio, Enrique M., Encinas, Cristina, Suarez Cabrera, Alexia, Bargay, Joan, Martinez Lopez, Joaquin, Gonzalez, Marta Sonia, Hernandez-Rivas, Jose Angel, Rosiñol, Laura, Hernández, Miguel-Teodoro, Paiva, Bruno, Cedena Romero, Maria Teresa, Puig, Noemi, Lahuerta, Juan-José, Bladé, Joan, San-Miguel, Jesús, Mateos, Maria-Victoria

Get full text

Supervised Machine Learning Improves Risk Stratification in Newly Diagnosed Myelodysplastic Syndromes: An Analysis of the Spanish Group of Myelodysplastic Syndromes by Mosquera Orgueira, Adrian, Perez Encinas, Manuel, Diaz Varela, Nicolas A, Mora, Elvira, Díaz-Beyá, Marina, Montoro, María Julia, Pomares, Helena, Ramos, Fernando, Tormo, Mar, Jerez, Andres, Nomdedeu, Josep F, De Miguel Sanchez, Carlos, Leonor, Arenillas, Cárcel, Paula, Cedena Romero, Maria Teresa, Xicoy, Blanca, Rivero, Eugenia, del Orbe Barreto, Rafael Andres, Diez-Campelo, Maria, Benlloch, Luis E., Crucitti, Davide, Valcárcel, David

Get full text

Making Clinical Decisions to Change Therapy Using Measurable Residual Disease Improves the Outcome in Multiple Myeloma by Martinez Lopez, Joaquin, Alonso Fernández, Rafael, Wong, Sandy W., Rios, Rafael, Shah, Nina, Cedena Romero, Maria Teresa, Ruiz-Heredia, Yanira, Sanchez, Jose M., Barrio Garcia, Santiago, Martin, Thomas, Wolf, Jeffrey L.

“…Background Measurable residual disease (MRD) testing in multiple myeloma (MM) is increasingly being utilized in clinical trials for the assessment of disease…”
Get full text

Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease by Lakhwani, Sunil, Rosiñol, Laura, Puig, Noemi, Pico Picos, Miguel Angel, Medina-González, Laura, Martinez Lopez, Joaquin, Paiva, Bruno, Cedena Romero, Maria Teresa, Oriol, Albert, Ríos, Rafael, Blanchard, María Jesús, Jarque, Isidro, Bargay, Joan, Moraleda, Jose Maria, Carrillo-Cruz, Estrella, Sureda Balari, Anna Maria, Krsnik, Isabel, Gonzalez Garcia, Esther, Casado Montero, Luis Felipe, Marti Tutusaus, Josep Maria, Encinas Rodriguez, Cristina, De Arriba, Felipe, Palomera, Luis, Sampol Mayol, Antonia, González-Montes, Yolanda, Motlló, Cristina, De la Cruz, Javier, Alonso Fernández, Rafael, Mateos, Maria-Victoria, Blade Creixenti, Joan, Lahuerta Palacios, Juan Jose, San Miguel, Jesus, Hernández Garcia, Miguel Teodoro

“…Introduction. Immunoparesis (IP) or the suppression of uninvolved immunoglobulins (Ig) is a very common finding in multiple myeloma (MM) patients at diagnosis…”
Get full text

Minimally Invasive Assessment of Measurable Residual Disease (MRD) in Multiple Myeloma (MM) by Gonzalez, Carmen, Lasa, Marta, Notarfranchi, Laura, Agullo, Cristina, Buenache Cuenda, Natalia, Zherniakova, Anastasiia, Castro, Sergio, Pérez, José Juan, Gonzalez-Calle, Veronica, Cedena Romero, Maria Teresa, Barrio, Santiago, Martín-Muñoz, Alejandro, Burgos, Leire, Alignani, Diego, Calasanz, Maria Jose, Rodriguez Otero, Paula, Rosiñol, Laura, De Arriba, Felipe, Ocio, Enrique M, Rocafiguera, Albert Oriol, Palomera, Luis, González-Montes, Yolanda, Sureda Balari, Anna Maria, Hernandez Garcia, Miguel Teodoro, Clavero Sanchez, Maria Esther, Ibanez Garcia, Angela, Gomez, Clara, Orfao, Alberto, Mateos, Maria Victoria, Lahuerta Palacios, Juan Jose, Bladé, Joan, San-Miguel, Jesus, Martinez-Lopez, Joaquin, Puig, Noemi, Paiva, Bruno

“…BACKGROUND MRD is an established test in MM clinical trials but not in routine practice. A hindrance to its wider adoption is invasive bone marrow (BM)…”
Get full text

Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial by Puig, Noemi, Agullo, Cristina, Contreras, Teresa, Paiva, Bruno, Cedena Romero, Maria Teresa, Pérez, José Juan, Aires, Irene, Martinez-Lopez, Joaquin, Rodriguez Otero, Paula, Gonzalez-Calle, Veronica, Gonzalez Perez, Marta Sonia, Gutierrez, Norma C., Rocafiguera, Albert Oriol, Ríos, Rafael, Rosiñol, Laura, Alvarez Rivas, Miguel Angel, Calasanz, Maria Jose, Joan, Bargay, Garcia-Sanz, Ramon, Gonzalez, Ana Pilar, Alegre, Adrián, Escalante, Fernando, Martínez, Rafael, De La Rubia, Javier, Teruel, Ana Isabel, De Arriba, Felipe, Palomera, Luis, Castro, Sergio, Hernández Garcia, Miguel Teodoro, López, Javier, García Mateo, Aránzazu, Ocio, Enrique M, Bladé, Joan, Lahuerta Palacios, Juan Jose, San Miguel, Jesús, Mateos, Maria Victoria

“…Background: GEM-CESAR trial is a potentially curative strategy for high-risk smoldering multiple myeloma (HRsMM) patients (pts) in which the primary endpoint…”
Get full text

Multiomics Profiling of Measurable Residual Disease (MRD) for Understanding the Biology of Ultra-Drug Resistance in Multiple Myeloma (MM) by Guerrero, Camila, Puig, Noemi, Cedena Romero, Maria Teresa, Goicoechea, Ibai, Burgos, Leire, Alignani, Diego, Lopez, Aitziber, Sarvide, Sarai, Calasanz, María José, Garcia-Sanz, Ramon, Martinez-Lopez, Joaquin, Rosiñol, Laura, Garcia, Esther González, Oriol, Albert, Rios, Rafael, Carrillo-Cruz, Estrella, Gonzalez Perez, Marta Sonia, Montes Gaisan, Carmen, De Arriba, Felipe, Arguiñano, Jose Maria, Marti, Josep M, Gonzalez-Montes, Yolanda, Garcia-Guiñon, Antonio, Lahuerta, Juan-José, Bladé Creixenti, Joan, Mateos, Maria-Victoria, San-Miguel, Jesús, Paiva, Bruno

Get full text

Protein Carbonylation Pattern Is Altered in Myelodisplastic Syndromes by Rodríguez García, Alba, Linares, Maria, Morales, Maria Luz, Garrido, Vanesa, Baquero, Irene, Cedena Romero, Maria Teresa, Sanchez, Ricardo, Ayala, Rosa, Bautista, Jose Manuel, Martinez Lopez, Joaquin

“…* A.R. and M.L. have contributed equally. Myelodysplastic syndrome (MDS) is a clonal disease that arises from the expansion of mutated hematopoietic stem…”
Get full text